Amanda has shaped and driven strategy in new fields of medicine and biotech through her 25-year career in biotechnology and data-driven drug development. She is a seasoned operator and business development expert with a strong track record of leading teams and driving transformational partnerships.
As a practicing acute-care hospitalist for more than a decade, Amanda has broad knowledge and deep experience in clinical medicine and care delivery. She is also a clinical trialist who has driven multiple clinical-stage drug development programs.
Currently, Amanda Banks is an Organizational Advisor to Harbinger Health. Before beginning in that role, Amanda was CEO and co-founder of Blackfynn, a data analytics company focused on improving medicines and care for people with neurodegenerative diseases. Prior to Blackfynn, she led Strategic Initiatives for Penn Medicine. Earlier in her career, Amanda led business development for the immunotherapy business unit of Maxygen, the first company to commercialize applications of directed molecular evolution, and for Valentis, a gene therapy company that pioneered non-viral gene-based therapeutics.
Amanda earned her M.D. degree from the University of Pittsburgh and a B.S. in Biology from Tufts University. She completed residency training in Internal Medicine at the University of Pennsylvania. She continues to take care of patients at the Veterans Affairs Hospital in Philadelphia.